Goodwin has been selected as one of seven U.S. law firms to join the approved advisor list for China’s Ministry of Commerce. View the full Law360 article here (subscription required).
Related Content
- AlertFebruary 27, 2023
NLRB Concludes that Separation Agreement Provisions Prohibiting Disparagement and Requiring Confidentiality of Agreement Terms Violate Employee Rights
- In the PressJanuary 27, 2023
Cannabis Marketing Proposed Regulations in New York & Neighboring States (Bloomberg Law)
- AlertJanuary 6, 2023
FTC Proposes a Sweeping Rule That Would Ban Nearly All US Noncompete Agreements
- Goodwin InsightsSeptember 20, 2022
3 Reasons Beauty Cos. Should Consider Pursuing Patents
- AlertAugust 10, 2022
Recent Court Decisions Shed Light on Enforceability of Electronic Contracts in the U.S.
- AlertJuly 28, 2022
Chief Judge of Western District of Texas Changes Waco Patent Case Assignment System
- AlertJuly 7, 2022
Fintiv 2.0: USPTO Director Issues Guidance Softening Risk of Discretionary Denial
- AlertMay 6, 2022
U.S. Government Authorizes Transactions Related to Patent Protection in Russia
- WebinarMarch 28, 2023
Reactions to Amgen v. Sanofi and the Future of Patent Law’s Enablement Requirement
- In the PressMarch 22, 2023
Goodwin Snags Tech and Life Sciences Litigation Trio (Commercial Dispute Resolution)
- In the PressMarch 22, 2023
Goodwin Adds 3 IP Litigators In NY (Law360)
- In the PressMarch 22, 2023
Goodwin Grows New York IP Litigation Practice by Three Partners (Bloomberg Law)
- Speaking EngagementsMarch 21, 2023
USC Gould School of Law's 2023 Intellectual Property Institute
- Press ReleaseMarch 21, 2023
Goodwin Welcomes Leading Technology and Life Sciences Litigation Team in New York
- In the PressMarch 21, 2023
Goodwin Welcomes Partner Group of IP Litigators (The American Lawyer)
- Press ReleaseMarch 20, 2023
OncoC4 Announces Strategic Collaboration with BioNTech to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications